Other large investors have also added to or reduced their stakes in the company. Notis McConarty Edward acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth $229,000. Baker BROS. Advisors LP acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth $769,000. Westover Capital Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth $579,000. Iguana Healthcare Management LLC boosted its stake in Alnylam Pharmaceuticals by 50.0% in the third quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biopharmaceutical company’s stock worth $5,083,000 after buying an additional 25,000 shares during the period. Finally, Opus Point Partners Management LLC boosted its stake in Alnylam Pharmaceuticals by 3.2% in the third quarter. Opus Point Partners Management LLC now owns 45,064 shares of the biopharmaceutical company’s stock worth $3,054,000 after buying an additional 1,380 shares during the period. 88.70% of the stock is currently owned by institutional investors.
Fayerweather Charles held its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to its most recent disclosure with the SEC. The firm owned 4,165 shares of the biopharmaceutical company’s stock at the end of the third quarter. Fayerweather Charles’ holdings in Alnylam Pharmaceuticals were worth $283,000 at the end of the most recent quarter.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 45.57 on Monday. The stock’s market capitalization is $3.91 billion. The stock’s 50 day moving average is $40.42 and its 200 day moving average is $52.34. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $80.11.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.02. The company had revenue of $17.50 million for the quarter, compared to analyst estimates of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The firm’s revenue was up 130.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.07) EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.01) EPS for the current year.
A number of equities research analysts have recently weighed in on the company. Vetr cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating and set a $41.90 price target on the stock. in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $68.00 price target (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday. JMP Securities set a $69.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 3rd. Ladenburg Thalmann Financial Services began coverage on Alnylam Pharmaceuticals in a report on Thursday, February 2nd. They set a “buy” rating and a $75.00 target price on the stock. Finally, Chardan Capital boosted their target price on Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, January 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $62.83.
In related news, CMO Akshay Vaishnaw sold 29,165 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $44.99, for a total transaction of $1,312,133.35. Following the sale, the chief marketing officer now directly owns 34,915 shares of the company’s stock, valued at approximately $1,570,825.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, January 25th. The shares were sold at an average price of $37.95, for a total transaction of $569,250.00. Following the sale, the director now directly owns 155,795 shares in the company, valued at $5,912,420.25. The disclosure for this sale can be found here. Insiders have sold a total of 59,165 shares of company stock worth $2,448,833 over the last ninety days. 4.00% of the stock is currently owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).